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2 
Summary 31 
Background. Pillar 3 of the End TB Strategy calls for the promotion of research and innovation at the 32 
country level in order to facilitate improved implementation of existing and novel interventions to end 33 
TB. In an era of increasing cross-border migration, there is specific need for integrating migration-related 34 
issues into national TB research agendas. The objective of this review is to provide a conceptual 35 
framework to guide countries in development and operationalization of a migrant-inclusive TB research 36 
agenda. Methods.  We conducted a literature review complemented by expert opinion and the previous 37 
articles in this State of the Art series to identify important themes central to migration-related TB. We 38 
categorized those themes into a framework for a migration-inclusive global TB research agenda across a 39 
comprehensive spectrum of research. We developed this conceptual framework taking into account: 1) 40 
the biomedical, social and structural determinants of TB; 2) the epidemiologic impact of the migration 41 
pathway; and 3) the feasibility of various types of research based on country’s capacity. Discussion. The 42 
conceptual framework presented here is based on the key principle that migrants are not inherently 43 
different from other populations in terms of susceptibility to known TB determinants, but they often have 44 
exacerbated or additional risks related to their country of origin and the migration process, which must be 45 
accounted for in developing comprehensive TB prevention and care strategies. A migrant-inclusive 46 
research agenda must systematically consider this wider context to have highest impact.   47 
  48 
 
 
3 
Introduction 49 
The End TB Strategy approved by the World Health Assembly in May 2014 aims to end the global 50 
tuberculosis (TB) epidemic in line with the Sustainable Development Goals (SDGs) by 2030, with the 51 
targets of a 90% reduction in TB mortality, a 80% decline in TB incidence, and no TB-affected household 52 
experiencing catastrophic costs due to TB1. The strategy relies on three fundamental pillars, including 53 
“intensified research and innovation”2. Promoting research across its entire spectrum (including basic 54 
science, clinical, epidemiological, health systems, and operational/implementation research (OR/IR)) is 55 
critical to maximizing the impact on TB reduction strategies in all, especially in vulnerable and high risk 56 
populations who have higher risks of TB infection and disease, as well as poor treatment outcomes.  57 
As described in previous articles within this series, migrants are often an especially vulnerable population 58 
due to the inherent risk of acquiring TB in high- and medium- burden countries, but also due to migration 59 
specific determinants3 that affect individuals in even low-burden countries. The first paper of the present 60 
State of the Art series reviewed how migrants should be considered as a special vulnerable group within 61 
the frame of the WHO End TB Strategy4. Growing surveillance data demonstrates the changing patterns 62 
of TB incidence due in part to migration flows3, 5. This last paper of the series builds upon previous articles 63 
in describing critical evidence gaps in the current knowledge of migration related TB issues that make 64 
migration-inclusive research a priority for TB prevention and care. The intention of this paper is not to 65 
present a prescriptive and comprehensive research agenda for TB in migrants, but to describe a systematic 66 
approach to establishing migrant-inclusive TB research agendas and to provide pragmatic considerations 67 
for operationalizing such agendas. 68 
Development of a conceptual framework for identifying evidence gaps and research priorities 69 
 
 
4 
In order to assess the current landscape of migrant-inclusive TB research, a non-comprehensive narrative 70 
literature review was conducted based on research areas defined in previous articles of this State of the 71 
Art series, including epidemiology, immunology, TB diagnostics, treatment, prevention, socio-economics 72 
and human rights. This review was based on a PubMed search using the keywords ‘tuberculosis OR TB’ 73 
AND ‘migrants OR migration OR refugees or asylum seekers’ AND ‘research AND operational OR 74 
implementation OR trials OR epidemiology OR social OR immunology’ from November 2015 through 75 
November 2017. A total of 204 papers were recovered that met search criteria and after abstract review, 76 
76 papers were found to be related to migration related TB policy or research questions. Of these, 36 77 
papers described some kind of “evidence gap” and were selected for more in-depth review. In addition, 78 
websites of main organizations contributing to aspects of TB in migrants (including WHO, International 79 
Organization for Migration (IOM), US Centers for Disease Control and Prevention (CDC), European 80 
Center for Disease Prevention and Control (ECDC), International Union Against TB and Lung Disease 81 
(The Union), and Médecins Sans Frontières (MSF)) were searched for evidence of ongoing or completed 82 
research activities related to migrants and TB.  From the review, three thematic areas emerged: first, the 83 
need for migrant-inclusive research that considers the determinants of TB for migrant populations, 84 
including the biological, social and structural determinants that are traditionally thought of as risk factors 85 
for TB; second, specific additional TB risks due to the migration process itself should be considered; and 86 
third, the need for research on how to operationalize migrant-inclusive programs and policies for TB 87 
prevention and care given feasibility and ethics.  88 
Based on these thematic areas, a conceptual framework was developed for systematically defining 89 
research priorities for TB in the context of migration at the country level. The framework suggests 90 
addressing migration related TB issues along three axes, adapted from the categories described above: 91 
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1)  Consideration of the general TB determinants (biomedical, social, and structural) within migrant 92 
communities.  93 
2) Consideration of the full migration pathway, from the country of origin, along the transitional or 94 
migration path, to the country of arrival (host country)3, 4.   95 
3) Consideration of the policies, practices and patient experiences along the cascade of care from 96 
prevention to diagnosis and treatment of TB.  97 
Mapping the existing country context along these axes may systematically identify research gaps and 98 
priorities that are context specific. We describe potential research questions that can be derived within 99 
classical research categories using this conceptual framework.   100 
 101 
Epidemiologic Research 102 
Despite a growing body of literature on the epidemiology of infectious diseases among migrants, critical 103 
evidence gaps remain. This section addresses the various risks of TB in migrants along the spectrum of 104 
the migration pathway, and how existing TB surveillance and data analysis systems may be mobilized to 105 
answer specific research questions. Considering TB burden in low-, medium-, and high-incidence 106 
countries, key epidemiological questions emerge. 107 
 108 
First, what are the specific effects of migration on TB: is migration a risk for TB, or a risk of poor outcome, 109 
or a mixture of these and others? There is substantial evidence that being a migrant from a high- or 110 
medium-burden country is a risk factor for TB in foreign-born persons living in a low-TB incidence 111 
country3,6, but how migration changes that risk still remains unclear.  For example, risk factors for 112 
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progression to active disease may be augmented due to poor general health, malnutrition, HIV infection, 113 
stress/anxiety, trauma, inadequate living conditions, or mental health disorders in vulnerable populations 114 
(including depression, bipolar disorders and psychosis) pre-migration as well as during and post-115 
migration. The investigation of migration related epidemiological risk factors and their impact on 116 
progression to active disease would assist in developing reliable mathematical models to project TB trends 117 
in migrants and the general population7. Such models are essential for forecasting and planning and, if 118 
combined with health economic modelling, can help targeting promising interventions to those 119 
determinants of TB most relevant to migrant populations8. 120 
 121 
Secondly, migration may exacerbate both individual and structural determinants of TB in populations 122 
already at risk9. As the causes and pathways of migration are heterogeneous, studies are needed that 123 
examine the epidemiologic and public health impact of differences across various types of migration 124 
pathways and categories of migrants - ranging from voluntary labor migrants to health care seeking 125 
migrants to destitute forced migrants traveling along dangerous routes with limited empowerment9. Most 126 
existing research focuses on descriptive epidemiology of TB in migrants post-arrival in the host country, 127 
demonstrating heightened social, economic and structural determinants of disease such as poverty, 128 
unemployment, and poor housing,10 but not much on specific factors relevant to the stage in migration3. 129 
A better understanding of TB risks associated with migration would help shaping appropriate multi-130 
sectoral policies (before, during, and after migration) to improve TB prevention and care in these 131 
populations. This is especially critical in low-incidence countries with a concentrated TB epidemic where 132 
the majority of TB cases are among the non-native born population. It is also relevant for high TB burden 133 
countries with a large number of migrants from other high burden countries,4,11 an often overlooked 134 
migration pathway.  135 
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 136 
Research is also needed to better understand TB transmission along migration routes whether migrant-to-137 
migrant transmission or migrant-to-native population transmission. The limited and heterogeneous 138 
existing data from molecular epidemiology do not provide enough evidence to measure the latter3,12. 139 
Moreover, findings can be hard to generalize, since transmission rates depend not only on the underlying 140 
risk in a migrant group but also on existing TB care and prevention strategies in a given setting and mixing 141 
patterns between the migrant and native population. Epidemiological research, including molecular 142 
epidemiology combined with health systems research may help identify gaps and opportunities for 143 
prevention of TB transmission. In this respect, careful attention should be paid to multi-drug resistant TB 144 
(MDR-TB) in migrants and research should be conducted to better characterize the burden of drug 145 
resistance in this population and its determinants13,14. 146 
 147 
The process of migration itself can have an impact on the relevance of TB-related policies, practices, and 148 
patient experiences. It is therefore critical to design and expand TB surveillance systems to monitor TB 149 
trends in different groups of migrants. Most countries that monitor TB rates in migrants lack detailed 150 
information about type of migrant, migration routes, time since arrival and risk profile3, 7. Such 151 
surveillance could inform more appropriate strategies for targeted testing and treatment of migrants with 152 
higher TB risk. This type of research can inform migrant-inclusive patient pathways of care as a first step 153 
in understanding migration specific gaps in health access, utilization, and health outcomes.  154 
 155 
Guidance exists on how to collect migrant-inclusive epidemiologic data. However, research is needed to 156 
assess the effectiveness of this type of guidance in resolving gaps in data and improving overall data 157 
management and quality. The ECDC, for example, has developed guidance for the collection of TB risk 158 
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factor data as part of routine surveillance15. As the majority of TB cases among migrants arise from 159 
reactivation of latent TB infection (LTBI) contracted in the country of origin3, there is a need to collect 160 
high quality data on prevalence of LTBI in different migrant risk groups, and link these to TB register 161 
data in order to determine reactivation rates and to identify additional determinants of disease. These types 162 
of additional surveillance components require additional health systems research.  OR/IR can then be used 163 
to develop targeted interventions to reduce the higher risk of reactivation in these groups.  164 
Operational and Implementation Research on the Patient Cascade of Care: Prevention, Diagnosis, 165 
and Treatment of TB  166 
Migrants from TB endemic countries are the largest TB risk group in a growing number of low-incidence 167 
countries and therefore require special attention when designing TB prevention and care activities3. 168 
Presently there is little consensus on the best interventions to target these populations, and there are limited 169 
data on the implementation of evidence-based guidelines on management of TB in migrant settings16-19. 170 
This may be due to the highly variable environments, conditions, and causes of migration that make 171 
standardized approaches challenging. Ensuring quality TB care (for active disease and latent infection) 172 
for migrants requires appropriate OR/IR at every stage of the patient cascade of care to understand how 173 
to optimize conditions for prevention, diagnosis, and treatment in each context11, 20. In this section, we 174 
focus on potential OR/IR categorized by each step in the patient cascade of care, with a focus on policies 175 
and programmatic practices relevant to prevention, diagnosis, and treatment of TB.  176 
TB Diagnosis: Intertwining of Latent and Active Disease 177 
Novel tools are needed to diagnose TB in general populations and differentiate the various stages of 178 
infection21. Especially in very mobile migrant populations, diagnostic tests need to be of high 179 
performance, easily operational, rapid and at the point of care so as to minimize losses to follow up. While 180 
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these characteristics certainly apply to the diagnosis of active disease (drug susceptible or drug resistant), 181 
new programmatic strategies should be developed for diagnosis of latent TB infection (LTBI). For these 182 
reasons, there is need for enhanced research to optimize the implementation of existing diagnostic tools 183 
and develop interventions to improve coverage of ‘hard to reach’ migrant populations, especially the most 184 
vulnerable groups like those who are undocumented and likely to be ‘missed’ by the health systems.  185 
 186 
Screening for latent TB infection. Treatment of LTBI has been identified as one of the potentially most 187 
powerful interventions for elimination of TB28, together with vaccination. Currently available tests to 188 
detect LTBI, the tuberculin skin test (TST) and the in vitro interferon-gamma release assays (IGRAs), 189 
measure an anamnestic response to M. tuberculosis antigens.  Based on the results of a meta-analysis of 190 
eight head-to-head studies that showed similar capacity of the 2 tests to ‘predict’ incident disease during 191 
short term follow-up, WHO recommends either test to identify healthy individuals that should be 192 
considered for LTBI treatment22 - of note, only one of the eight studies had been conducted in migrants23, 193 
which suggests that additional research should be conducted inclusive of this population. 194 
 195 
Evidence for the best targeted testing strategy for LTBI in migrants is still limited. Several studies suggest 196 
that screening with a single-step IGRA is more cost-effective than TST screening24-26. However, a 197 
modelling study comparing different LTBI screening strategies in non-native born entrants to Canada 198 
found that sequential screening with TST followed by IGRA was more cost-effective than each of these 199 
alone27. The capacity of both TST and IGRAs to predict incident TB in individuals with a positive result 200 
is very low, with the number needed to treat [NNT]) to prevent one case of active disease of 67 for TST 201 
and 37 for IGRAs28. LTBI screening efficiencies in migrants specifically are unknown. Additional 202 
research is needed to improve LTBI diagnostic tools and screening strategies. 203 
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 204 
A new model of TB natural history has been proposed that considers a continuous spectrum from 205 
spontaneous clearance of bacteria to quiescent infection to disease29. The prolonged asymptomatic phase 206 
of early disease during which pathology evolves prior to clinical presentation of active disease is defined 207 
as ‘incipient TB’ 30. According to this scenario, diagnostic tests for LTBI should be conceptually 208 
categorized into two categories: 1) test for persistent infection; and 2) test for incipient TB31. Despite 209 
recent progress in identifying genomic signatures that are correlates for risk of progression32, tests of either 210 
persistent disease or incipient TB are not yet commercially available (although one RNA based PCR test 211 
is in clinical trial33). While such a test could improve targeting of infected patients, the role of fluctuating 212 
TB determinants that change as a result of the migration pathway (eg nutrition), should be addressed in 213 
the evaluation of these novel tests. Based on these new diagnostic developments, a subsequent research 214 
area is to develop new treatment regimens for incipient TB. The powerful impact that such new tools 215 
would have not only on migrant populations but for global TB control emphasizes the need for basic and 216 
clinical research in this field.  217 
 218 
Screening and Diagnosis of active disease.     219 
Current challenges in screening for active TB among migrants are similar to those in other high-risk 220 
populations. The limitations of existing tests are the low sensitivity and specificity of smear microscopy 221 
and the need for laboratory expertise and long growth times required for culture-based methods34.  In 222 
addition, screening for TB in migrants face the operational challenges of provision of rapid care in a 223 
potentially mobile population with often limited health care access. Therefore, a migrant-inclusive TB 224 
research agenda must include an evaluation of not only technologies, but also of new strategies for 225 
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screening and diagnosing active TB. These interventions may include active case finding using symptom 226 
screen, chest radiography, or other strategies17, 35. 227 
 228 
Several existing diagnostic tests and strategies have the potential to address TB diagnostic challenges in 229 
migrants. These include molecular methods, such as the XpertMTB/RIF assay, Xpert Omni,36 and Xpert 230 
MTB/RIF Ultra assay (Ultra) (Cepheid, USA), which have been recommended for use in a variety of 231 
populations by WHO37,38 as well as tests such as urinary lipoarabinomannan (LAM) detection, 232 
Mycobacterium tuberculosis complex loop-mediated isothermal amplification (TB-LAMP), and 233 
molecular line probe assays for drug resistance. Although the need for point-of-care tests is even more 234 
flagrant in mobile populations, none of these diagnostic tools have been operationally evaluated in migrant 235 
populations39-41.  OR/IR is needed to assess feasibility and effectiveness of these diagnostic tests in 236 
migrant-inclusive settings, to identify mechanisms for scale up, and to improve linkages to care.  237 
 238 
Access to Care and Treatment Adherence. Migrant communities often face barriers to accessing health 239 
services. While all migrants should have the right to healthcare services42, 43, there is limited information 240 
on the ability of migrants to access care when they experience symptoms and signs of TB along the 241 
migration pathway. Studies from several EU host countries showed that access to medical services may 242 
be restricted44, 45, and often depends on the type of residence permit the migrant holds 46. Since access to 243 
health care is essential for early diagnosis and treatment of TB, identifying the gaps and testing 244 
interventions that can improve access to health services for all types of migrants is needed, particularly 245 
for implementing quality TB care. For example, while it was shown using mathematical models that 246 
screening high risk subpopulations with IGRAs had the potential for high cost effectiveness which was 247 
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conducive to policy change, lack of empirical effectiveness data in these subpopulations was identified as 248 
a barrier to effective implementation of a targeted testing and treatment strategy47.  249 
 250 
Migrants with TB often have lower treatment success rates compared to native individuals48-51. 251 
Understanding the underlying reasons for this is critical and context-specific. Several studies have shown 252 
that even at the subnational level, identifying and targeting factors associated with default or loss to follow 253 
up can improve health systems responses to TB treatment provision for migrant populations49, 50, 52. For 254 
instance, a systematic review evaluating reasons for non-adherence to treatment in 5 continents described 255 
heterogeneous TB treatment outcomes among migrants due to variability in legal status and social risk 256 
factors such as education, employment and access to care53. This heterogeneity may be particularly 257 
important when evaluating the full potential of novel treatment strategies such as short-course treatment 258 
regimens for drug resistant disease, the use of digital health technologies to support treatment adherence54, 259 
55, and planning for scale-up of treatment programs53. The critical point is that context-specific data are 260 
required to understand how best to support migrants in initiating and completing treatment. Such evidence 261 
can then expand to health systems research and policy change for creating mechanisms and application of 262 
legal frameworks for cross-border TB control that facilitate access to care. 263 
Social Protection Research 264 
The majority of migrants are exposed to socioeconomic vulnerabilities along the migration pathway from 265 
country of origin to country of destination, including those associated with 3: 266 
1) social, biological, and structural determinants of TB in their country of origin, in transit, and in 267 
host country; 268 
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2) the migration process/transit (malnutrition, trauma, violence, mental health issues, substance 269 
abuse, including alcohol and smoking); 270 
3) the living conditions in the country of transit/destination (poor housing quality, crowding, 271 
inadequate working conditions, poor nutrition, food insecurity); and 272 
4) the limited access to health care services both during transit and in the country of destination, 273 
often due to language, economic and cultural barriers.  274 
All these features of poverty and vulnerability point to substantial needs for social protection, defined as 275 
a set of policies and programmes aimed at reducing the social and economic risk for those who need to 276 
access and receive care10.  277 
Social protection strategies have shown promise as a way to improve treatment outcomes among TB 278 
affected households with significant socioeconomic risk56, 57. However, even in settings where social 279 
protection schemes have shown benefit in TB outcomes, operationalizing these strategies in migrants 280 
may pose significant challenges58. Research is required that systematically assesses migrants’ 281 
vulnerabilities and their social and economic barriers to care to identify where and when in the migration 282 
pathway social protection interventions should be deployed.  Understanding and evaluating the benefit 283 
of TB-sensitive approaches (social protection schemes for which TB patients may be eligible based on 284 
criteria unrelated to their disease) versus TB-specific approaches (social protection schemes for with TB 285 
disease is an eligibility criteria) will be required in understanding how to operationalize these 286 
interventions. These vulnerabilities as well as barriers to care are unlikely to be significantly different 287 
from those observed among non-migrant populations when accounting for socioeconomic status, but 288 
migration is likely to exacerbate them. Research is required to understand the full effect of this 289 
potentiation and identify suitably targeted social protection interventions. 290 
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Despite a growing body of evidence that suggests the positive impact of cash transfer schemes on TB 291 
and economic outcomes57, 59-61, we are not aware of such studies among migrants62. While health 292 
policies in some countries include access to social protection for any legal resident, there is limited 293 
information on how such effective policies may translate to migrant populations with similar 294 
socioeconomic characteristics but without a legal status56, 61, 62. Research on how to operationalize social 295 
protection and measure the effect of economic support and welfare 2, 63, 64on TB outcomes in migrant 296 
populations is needed to inform development of suitable social protection schemes both in high- and 297 
middle-income host countries65. Examples of such research include studying the feasibility and impact 298 
of a cash transfer for migrants diagnosed with TB or the impact of short-term disability insurance at the 299 
time of treatment initiation. High-quality operational/implementation research on social protection that 300 
includes migrants would contribute to reaching the targets of the End TB Strategy within the larger 301 
context of the SDGs66.  302 
 303 
Creating and Operationalizing a Migrant-Inclusive Research Agenda  304 
While high- and medium-burden countries are developing national TB research agendas in keeping with 305 
Pillar 3 of the End TB Strategy, very few, if any, specifically address the particular challenges of TB 306 
prevention and care in migrants. To properly inform national and international policies to improve 307 
migrants’ health with particular reference to TB, a research agenda is needed at the global and country 308 
level that: (i) draws from a context-specific and migrant-inclusive situational assessment; (ii) engages a 309 
variety of partners including those from migrant communities; (iii) leverages supranational or regional 310 
networks; (iv) draws on political leadership; and (v) includes ethical and accountable mechanisms for 311 
implementation and dissemination. 312 
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The research and innovation pillar of the End TB Strategy2 promotes the need for well-designed and 313 
empirically grounded research. To facilitate this, WHO has developed the Global Action Framework for 314 
TB Research67 and a Toolkit68 for developing national TB research agendas. These tools may be used to 315 
develop context-specific research questions related to the challenges of eliminating TB in migrant 316 
populations and to ensure that the national TB research agendas being developed are migrant-inclusive. 317 
Such research agendas will benefit from engaging stakeholders with expertise in migration, epidemiology, 318 
demography, biomedicine, health systems, and other social sciences in the identification of research 319 
priorities to improving the health of the migrant population. The participation of the migrant community 320 
is necessary to guarantee the proper consideration of the migrant perspective - for example, in addressing 321 
the impacts of migrant/refugee status, ethnicity and socioeconomic status on health service access and 322 
utilization.  323 
Countries establishing migrant-inclusive TB research agendas should consider multi-country agreements 324 
that harmonize research priorities, such as between migrants’ countries of origin and destination (both 325 
high and low TB burden countries). This can be achieved through national or regional TB and migration 326 
research platforms that would allow for transnational linkages critical for building capacity and 327 
disseminating knowledge and innovation. Such platforms, or research “hubs”, may be powerful in 328 
monitoring TB control efforts in migrants, advocating for political and financial commitment, 329 
strengthening institutional and community capacities and ensuring the collaboration necessary to address 330 
this issue head on11. Political leadership is needed to prioritize an innovative TB response through an 331 
integrated and multi-disciplinary research approach. The time is ripe for such political commitment, in 332 
light of the recent WHO Ministerial Meeting on Tuberculosis convened in Moscow in November 2017 333 
and in preparation for the discussion of TB at the 2018 United Nations General Assembly.   334 
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Finally, migrant communities should be engaged in research prioritization from the outset, including in 335 
research implementation and dissemination of findings. Migrant populations may not have adequate rights 336 
or representation as granted to citizens within national legislation. Therefore, researchers must ensure that 337 
adequate international and national legislative frameworks on research ethics and data protection are 338 
applied69. Researchers must have a strategy to address issues of privacy, informed consent, coercion, and 339 
social and psychological distress or trauma. Protection and promotion of human rights, ethics and equity 340 
is one of the fundamental principles underpinning the End TB Strategy2. For migrant populations, 341 
promoting and protecting their health and respecting, protecting and fulfilling human rights are 342 
inextricably linked. A migrant-inclusive TB research agenda should address evidence-based solutions that 343 
respect, protect and fulfil migrants’ human rights.  344 
 345 
Conclusion 346 
Identifying and pursuing a migration-inclusive TB research agenda is critical for advancing our 347 
understanding of TB among migrant populations and improving TB prevention and care worldwide. In 348 
this review, we propose a conceptual framework for constructing migrant-inclusive research agendas at 349 
national and multi-national levels, and present areas of particular focus for research in countries attempting 350 
to address TB diagnosis, treatment and prevention in migrant populations (Table). To achieve the 351 
ambitious targets of the End TB Strategy and align with the SDGs, migration-inclusive health policies and 352 
programs are needed now more than ever.   353 
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Table. Suggested Migration-Inclusive TB Research Agenda 537 
Research Approach Research Priority Areas 
Epidemiological Research  Identify TB/LTBI risks and heterogeneity specific to the migrant population 
at all points along the migration pathway  
 Refine use of molecular epidemiology to determine clustering, transmission 
dynamics, and reactivation rates in migrant populations throughout the 
migration pathway 
 Describe risk factors for all types of migrants 
 Describe MDR epidemiology in migrants 
 Optimize cross-border surveillance and epidemiological analysis of TB and 
migration between high-burden countries 
 Assess LTBI prevalence stratified by risk factors such as gender, age, 
socioeconomic status, country of origin, and situation along the migration 
pathway 
 Assess the epidemiologic impact of migration as healthcare seeking, 
especially for patients with drug resistant TB  
Basic and Clinical Research  Develop novel diagnostic tests for LTBI that meet test performance needs 
for migrant populations including children. 
 Assess efficacy and effectiveness of novel short course regimens (4-6 week 
therapy) for prevention of TB for migrant populations including children 
 Develop of point of care diagnostic tests that meet test performance needs 
for migrant populations including children 
 Develop of high efficacy short course regimens for treatment of TB 
 Elaborate host-pathogen interactions with more specificity to inform 
diagnostic and therapeutic development 
 Characterize the effect of modifiable TB social and structural determinants 
that affect immune response to the pathogen 
 Assess prevention and treatment of migrants who are contacts of drug-
resistant patients to prevent disease 
 
Operational and 
Implementation Research 
 
---Prevention and Screening  Evaluate feasibility of LTBI targeted testing and treatment algorithms on 
migrants at key points along the migration pathway 
 Assess the use of mobile health (mHealth) and digital health technologies to 
support linkage to care and treatment adherence in migrant populations 
 Evaluate the operational impact of LTBI screening tools (both pre-and post-
arrival)  
---Diagnostics  Evaluate specific evidence-based diagnostic guidelines in migrant 
populations as compared to native populations 
 Identify health systems and patient barriers to implementation of diagnostic 
testing strategies in migrants 
---Treatment  Establish the comparative effectiveness of treatment strategies (e.g. DOT 
versus SAT) 
 Evaluate the impact of novel treatment regimens including short course 
therapy in migrants when implemented in programmatic settings 
 Identify core components of interventions needed to maximize treatment 
adherence 
 Pilot mechanisms to ensure that culture and drug susceptibility results are 
communicated to providers treating a patient along the migration pathway 
Health Systems and Health 
Economics Research 
 Evaluate cost- and cost effectiveness of migrant-focused TB interventions 
 Analyse gaps in health system access specific to documented and 
undocumented migrants along the migration pathway 
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 Establish critical components necessary for operationalizing cross-border 
collaborations 
Social Protection Research  Identify context-specific social and economic vulnerabilities in migrants 
 Identify targetable socioeconomic barriers to TB care for migrants 
 Evaluate the effectiveness and impact of social protection strategies on 
reducing vulnerabilities and improving public health and TB outcomes in 
migrants 
 Understand the contextual requirements for including migrants in social 
protection schemes 
 Identify and evaluate TB-sensitive and TB-specific interventions on 
migrant health 
Health and Human Rights 
Research 
 Document infringements on human rights of TB programmes 
 Develop TB specific interventions that support the human rights of 
migrants 
TB Tuberculosis, LTBI Latent iuberculosis infection, DOT Directly observed therapy, SAT Self-538 
administered therapy, MDR Multidrug resistant tuberculosis 539 
